Dr. Braden Manns looks at the idea of boss with respect to physicians and what it can mean to patients.
Dr. Braden Manns looks at the idea of boss with respect to physicians and what it can mean to patients.

Click here or on the above image to read the letter.

“‘Whether it’s not having a family doctor, whether it’s ambulances or emergency room waits, cancer care, or waitlist for surgery. They’re increasingly worried that they cannot get the help they need when they need it, and theyre worried that the changes that are happening are making that worse.'”
Click here to read the full article.
Dr. Paul Parks shares some healthcare-related concerns with Ryan Jesperson on @realtalkrj.

If you have not watched the associated CTV video, you may want to do so.
“‘How many more patients have to die in our waiting room before they step up and show some leadership?'”

There is much discussion around the need for transparency in the healthcare sector, with patient advocacy groups being a strong voice in this discussion. However, what about their own transparency?
“Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database logging 12,000 donations from large publicly traded drugmakers to such organizations….
The database, called “Pre$cription for Power,” shows that donations to patient advocacy groups tallied for 2015 — the most recent full year in which documents required by the Internal Revenue Service were available — dwarfed the total amount the companies spent on federal lobbying. The 14 companies that contributed $116 million to patient advocacy groups reported only about $63 million in lobbying activities that same year.
Click here to read the full article.